| First Author | Wang C | Year | 2021 |
| Journal | Cell Rep | Volume | 37 |
| Issue | 8 | Pages | 110021 |
| PubMed ID | 34818534 | Mgi Jnum | J:349191 |
| Mgi Id | MGI:6881803 | Doi | 10.1016/j.celrep.2021.110021 |
| Citation | Wang C, et al. (2021) Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell Rep 37(8):110021 |
| abstractText | Treatments aiming to augment immune checkpoint blockade (ICB) in cancer often focus on T cell immunity, but innate immune cells may have important roles to play. Here, we demonstrate a single-dose combination treatment (termed AIP) using a pan-tumor-targeting antibody surrogate, half-life-extended interleukin-2 (IL-2), and anti-programmed cell death 1 (PD-1), which primes tumors to respond to subsequent ICB and promotes rejection of large established tumors in mice. Natural killer (NK) cells and macrophages activated by AIP treatment underwent transcriptional reprogramming; rapidly killed cancer cells; governed the recruitment of cross-presenting dendritic cells (DCs) and other leukocytes; and induced normalization of the tumor vasculature, facilitating further immune infiltration. Thus, innate cell-activating therapies can initiate critical steps leading to a self-sustaining cycle of T cell priming driven by ICB. |
